ARG1 and cancer: The inhibition of ARG1 and ARG2 activity has shown positive results across numerous cancer models by reducing myeloid-driven immune suppression (164), however, there were only 2 studies assessing ARG1 and ARG2 in cancer patients at the beginning of 2023 (31).